Encapsulated and nonencapsulated strains of Staphylococcus aureus which lack coagulase or clumping factor (bound coagulase), or both, were examined for the antigen associated with the fibrinogen-cell clumping reaction. Extracts of the cells were tested for the ability to react with fibrinogen or to inhibit fibrinogen precipitation. Antisera prepared against encapsulated (coagulase-positive, clumping factor-negative) variants, as well as against nonencapsulated wild-type (coagulasepositive, clumping factor-positive) S. aureus strains, contained high titers of clumping-inhibiting antibody. When coagulase-negative, clumping factor-negative mutants were the immunizing agents, antisera contained no demonstrable clumpinginhibiting antibody. Phenol extracts of all coagulase-positive strains tested precipitated fibrinogen, regardless of the ability of cells to clump in the presence of fibrinogen. Polysaccharide extracts of encapsulated, clumping factor-negative strains inhibited this fibrinogen-precipitating activity, whereas similar extracts of nonencapsulated staphylococci did not inhibit the fibrinogen reaction. From these results, it appeared that the coagulase-positive, encapsulated staphylococci which do not clump in fibrinogen solution possess clumping factor, but that their capsular polysaccharide inhibits clumping activity. These findings suggested a closer association of clumping factor and coagulase than is now recognized.
In 1931, Gilbert (4) reported the isolation of an encapsulated strain of Staphylococcus aureus which was highly virulent for guinea pigs. More recently, encapsulated staphylococci, particularly the Smith strain, have received considerable attention because of their remarkable virulence for mice (1, 7, 9, 16) . Characteristically, such coagulase-positive, encapsulated staphylococci form diffuse colonies in plasma-soft or fibrinogensoft agar and their cells do not clump in the presence of fibrinogen, whereas typical strains of S. aureus produce compact colonies and are positive for the clumping factor (bound coagulase) reaction. The exceptional virulence of the encapsulated staphylococci has been attributed to the antiphagocytic activity of their capsules (9) . An antigenic polysaccharide which is a surface component of the Smith strain has been associated with this organism's ability to resist phagocytosis and has been used to immunize mice against staphylococcal disease (10) . Apparently, other encapsulated strains also possess this polysaccharide antigen which is reported to be a potent immunizing agent in man and certain animals (3) . Indeed, serological diversity of mouse virulent and avirulent variants within the Smith strain was first suspected when it was noted that two different colony types were produced in serum-soft agar (7) .
The distinguishing in vitro features of such virulent S. aureus strains appear to be the presence of a capsule and the absence of clumping factor. Apparently, stable strains of coagulase-positive, clumping factor-negative staphylococci are regularly encapsulated. Two such strains, K6 and K93, which were isolated in this laboratory, have remained stable with respect to this combination of properties since 1956. Unless the encapsulated staphylococci actually lack clumping factor, these observations suggest that the capsule may interfere with the fibrinogen-cell clumping reaction. To determine whether this occurs, encapsulated staphylococci were examined for antigenic activity associated with clumping factor, and their extracts were tested for the ability to react with fibrinogen or to inhibit the staphylococcalfibrinogen reaction, or both. Throughout the study, encapsulated staphylococci were compared with typical, nonencapsulated S. aureus strains 799 Staphylococcal strains. Ten staphylococcal strains were examined for the clumping factor antigen. Nonencapsulated strains, which were positive for both coagulase and clumping factor, included the mouse avirulent, compact colony type Smith (S) variant (7) , a strain designated J17 by K. Jensen, and two typical S. aureus strains, H and 604, isolated in this laboratory from clinical specimens. Mutant strains Hv2, J17M, and 604M, all of which were negative for both coagulase and clumping factor, were derived from strains H, J17, and 604, respectively. Strain Hvl is a coagulase-negative, clumping factor-positive mutant of strainH. Encapsulated, coagulase-positive staphylococci, which do not slump in the presence of fibrinogen, included three mouse virulent strains, namely, the diffuse colony type Smith (Sv) variant (7) and our isolates K6 and K93.
Preparation ofantisera. Cells to be used as vaccines were harvested from 18-hr (37 C) agar cultures and were suspended in sterile phosphate-buffered saline, pH 7.4. Rabbits were immunized with a heated (2 hr at 65 C) cell suspension containing approximately 109 cells/ml, of which a small proportion (less than 1%) were viable staphylococci. Increasing doses (0.5 ml to 1.0 ml) of the cell suspension were injected intravenously, twice weekly, over a period of 6 weeks.
Preparation of extracts. Cell extracts of encapsulated and nonencapsulated strains were examined for a fibrinogen-reacting substance which Kato and Omori (8) had extracted from cells of a clumping factorpositive staphylococcus. The 90% phenol method of Kato and Omori was modified by extracting cells at 4 C for 30 min with 45% phenol; this method yielded a water phase as well as a phenol phase. After centrifugation, the phenol phase was separated from the water phase, washed several times with distilled water, and then extracted repeatedly with ethyl ether to remove phenol. The phenol extract was concentrated by lyophilization and was rehydrated in distilled water to contain 1 mg of protein per ml, as determined by the biuret reaction (5). The water phase was dialyzed extensively against distilled water, concentrated at 40 C under vacuum, and adjusted to standard (2 mg/ml) carbohydrate content. When the extract was of an encapsulated strain, carbohydrate content was determined by the method of Haskell and Hanessian (6) , whereas, in the case of extracts of nonencapsulated strains, the anthrone method of Scott and Melvin (14) was used for the carbohydrate determination. The acetic acid method described by Fisher, Devlin, and Erlandson (3) was also applied to cells of the encapsulated stains for extraction of polysaccharide, and, hereafter, these extracts are designated the polysaccharide extracts to differentiate them from the carbohydrate-containing water-phase extracts obtained by the phenol procedure.
Serological tests. The capacity of immune serum to inhibit the fibrinogen-cell clumping reaction was determined by a two-step test (12) . Equal volumes (0.5 ml) of a standard cell suspension of a clumping factor-positive staphylococcus and increasing dilutions of antiserum were mixed in serological tubes and the tubes were held at room temperature for 2 hr. After this incubation period, 0.1 ml of 0.5% human fibrinogen (Merck Sharpe and Dohme Research Laboratories, Rahway, N.J.) saline solution was added to each tube. This concentration of human fibrinogen was well in excess of that required to cause clumping of the cells of any strain tested. Tubes were shaken for 5 min and were promptly observed for cell clumping.
Cellular extracts were analyzed for their antigenic properties by double diffusion in agar-gel (11) and by immunoelectrophoresis (13) .
Fibrinogen reactions. The ability of phenol-and water-phase extracts to precipitate fibrinogen was tested by layering an equal amount of extract and 2% bovine fibrinogen (Armour fraction I; Armour and Co., Chicago, Ill.) or human fibrinogen (Merck Sharpe and Dohme Research Laboratories) saline solution in a capillary tube. To rule out nonspecific precipitation of protein, our controls included capillary tubes containing saline and extract, fibrinogen and saline, and extract and 2% bovine serum albumin (Armour fraction V; Armour and Co.). Tubes were fixed in a clay block and were observed by indirect light.
To ascertain the effect of capsular polysaccharide on the fibrinogen-precipitating activity of phenol extracts, equal volumes of phenol extract and polysaccharide extract were mixed, and the mixture was reacted with fibrinogen in the capillary tube test. Water extracts, resulting from the 45% phenol extraction of nonencapsulated and encapsulated staphylococci, were similarly tested for their ability to inhibit precipitation of fibrinogen. Saline was substituted for polysaccharide extract or water extract in control tubes.
RESULTS
Fibrinogen-cell clumping inhibition by antisera. Results of clumping inhibition tests, expressed as reciprocals of inhibiting titers, are shown in Table 1 . Antiserum prepared against any of the coagulase-positive strains, including the encapsulated, clumping factor-negative staphylococci, inhibited the clumping of all clumping factorpositive strains tested. These results indicate that, although they do not clump in the presence of fibrinogen, the encapsulated staphylococci possess the antigen associated with clumping factor. All sera taken from rabbits before immunization were negative for clumping-inhibiting antibodies against the strains tested. In no instance was the fibrinogen-cell clumping reaction inhibited by serum of a rabbit which had been immunized with a coagulase-negative, clumping factor-negative mutant. Precipitation of fibrinogen by extracts. As shown in Table 2 , phenol extracts of all coagulasepositive staphylococci, regardless of their clumping factor reaction, precipitated both human and bovine fibrinogen. Negative results were obtained with the phenol extract of the one coagulasenegative, clumping factor-negative mutant (J17M) strain tested. Fibrinogen was precipitated, however, by the phenol extract of strain Hvl, which is negative for coagulase but positive for clumping factor. Water extracts of all strains were negative in the fibrinogen precipitation test. None of the extracts precipitated bovine serum albumin.
Effect of capsular polysaccharide on fibrinogen precipitation. Both the polysaccharide extracts and the water-phase extracts of the encapsulated strains inhibited the fibrinogen-precipitating activity of phenol-phase extracts (Table 3) . When hyaluronic acid or dextran was substituted for staphylococcal polysaccharide in these experiments, fibrinogen precipitation by phenol extracts was not inhibited. Water-phase extracts of nonencapsulated strains were also unable to inhibit fibrinogen precipitation by phenol extracts.
DIscussIoN
By ruling out the absence of clumping factor as a distinguishing feature of mouse-virulent strains of S. aureus, the present findings further emphasize the importance of the staphylococcal capsule as a factor in the unusual pathogenicity of these stains. Detection of clumping factor in encapsulated staphylococci which do not exhibit the fibrinogen-cell clumping reaction reveals a closer association of clumping factor and coagulase than is now acknowledged. To date, attempts to inhibit the clumping of S. aureus cells in fibrinogen solution by prior treatment of the cells with polysaccharide extracted from an encapsulated staphylococcus have been unsuccessful. Possibly, the concentration of polysaccharide in the extract was not sufficient to be effective, or the site of binding between the clumping factor and polysaccharide was not accessible to the polysaccharide at the outermost surface of the cell.
In this study, the ability to inhibit fibrinogen precipitation was restricted to extracts of encapsulated staphylococci. Moreover, all extracts which caused inhibition of fibrinogen precipitation con- 
